Selexys Pharmaceuticals Corporation - Recruiting 16 years to 65 years. - A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises.
Gamida Cell ltd - Recruiting 2 years to 21 years. - Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease.
Mast Therapeutics, Inc. - Recruiting 4 years to 65 years. - Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis.
National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years. - Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease, Thalassemia, and Diamond Blackfan Anemia.
National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older. - Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia.
Thomas Jefferson University - Recruiting 18 years to 45 years. - Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors.
Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis
University of Texas Southwestern Medical Center - Recruiting 18 years to 45 years. - Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia.
St. Jude Children's Research Hospital - Recruiting 12 years to 30 years. - Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program.
Duke University - Recruiting 18 years or older. - Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects.
Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)
Sidney Kimmel Comprehensive Cancer Center - Recruiting 2 years to 70 years. - A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies.
NKT Therapeutics - Recruiting 18 years to 60 years. - A Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of Intravenous NKTT120 in Adults With Stable Sickle Cell Disease.